713-P: Glycemic Outcomes of New Inpen Smart Insulin Pen Users Who Received Virtual Onboarding Support

Background and Aims: The InPen™ smart insulin pen is FDA-cleared for self-start therapy from home due to its simplicity and ease of setup. New users were offered virtual onboarding support that included a personalized review, optimization of key features, and benefits of use (e.g., dose calculator, active insulin, in-app reminders, and report generation). This study assessed glycemic outcomes achieved by users who received onboarding support and users who did not. Methods: InPen™ users (N=2,534) with ≥30 days of distinct InPen™ and CGM data were categorized into one of three groups based on virtual onboarding support provided from April-August 2020: A. No support, unable to reach, B. Basic tech support, declined onboarding and C. Onboarding support. Glycemic outcomes (GMI, CV, TIR, TAR, and TBR) were compared and analyzed using ANOVA testing. Results: Table 1 shows that users who received virtual onboarding support (Group C) demonstrated significantly improved glycemic outcomes when compared to users who did not (Group A). No difference was observed in TBR across all groups. Conclusions: Future efforts should evaluate methods that increase device and feature engagement during the self-start and onboarding processes to optimize diabetes self-management behaviors and glycemic control. Disclosure M. Smith: Employee; Self; Companion Medical, Medtronic. G. Im: Employee; Self; Companion Medical, Medtronic. A. Gaetano: Employee; Self; Companion Medical, Medtronic. S. Thanasekaran: Employee; Self; Companion Medical, Medtronic. J. Macleod: Employee; Self; Companion Medical, Medtronic.